TRACER：面向癌症药物基因组学模型与患者肿瘤的响应保护跨域对齐框架
TRACER: response-protected cross-domain alignment of cancer pharmacogenomic models with patient tumors
TRACER 是一个端到端框架，通过监督式药物响应预测、生物条件约束的邻居对齐和响应保护梯度调控，实现从细胞系到未标注患者肿瘤的跨域迁移。在 ModelID 不重叠的已见药物划分上，TRACER-Full 在按药物 z 标准化的测试对上取得全局 Pearson 相关系数 0.5125 ± 0.0192，而仅响应模型为 0.5179 ± 0.0193，平均差 −0.0054；在排除对齐的 TCGA 审计样本中，致癌 Hallmark 邻居一致性平均提升 0.1162 ± 0.0210。
来源：Briefings in Bioinformatics · doi.org
Pharmacogenomics integrates tumor molecular features with drug responses to support precision oncology, but biological domain shifts and optimization conflicts hinder transfer from screened cell lines to unlabeled patient tumors. We developed TRACER (Transfer of Response Across domains via Conflict-aware End-to-end Regulation), an end-to-end framework combining supervised drug-response prediction, biologically conditioned neighbor alignment and response-protected gradient regulation. By projecting only conflicting components of the auxiliary alignment gradient, TRACER preserves the response-optimization direction learned from experimental labels. Across ModelID-disjoint, seen-drug splits, TRACER-Full achieved a global Pearson correlation of 0.5125 $\pm $ 0.0192 on per-drug z-standardized test pairs, compared with 0.5179 $\pm $ 0.0193 for Response-only, a mean difference of $-0.0054$. Mean oncogenic Hallmark neighbor consistency increased by $0.1162 \pm 0.0210$ in alignment-excluded The Cancer Genome Atlas audit samples. At the patient level, a source-validation-defined drug partition and uniform stability analysis supported four predicted pharmacological response subtypes (PRSs) in breast invasive carcinoma (BRCA), four in uterine corpus endometrial carcinoma (UCEC) and two in sarcoma (SARC). PRS-construction-excluded drugs characterized distinct predicted mechanism-level profiles, and pan-cancer indication recovery provided a lineage-aware internal consistency assessment of the patient rankings. TRACER provides an interpretable and auditable framework for response-preserving cross-domain alignment and it generates patient pharmacogenomic hypotheses for subsequent functional validation.